Options for the clinical management of obesity are currently limited to surgery, a few devices and a small (and dwindling) selection of drugs. Â The effort to add to these options is as large as the growing opportunity to do so, with many companies pursuing a wide range of interventions while the ballooning prevalence of obesity drives the process.
The result is that the current landscape of clinical options will change considerably over the next few years, with options to manage the overweight and obese encompassing the following:
- satiety drugs
- malabsorption drugs
- appetite suppression drugs
- combination drugs
- restrictive devices
- artificial fullness devices
- malabsorption devices
- gastric emptying devices
- appetite suppression devices
As existing options find more or less acceptance among clinicians and patents, and as new options gain approval and adoption, the resulting balance of obesity product revenues will undergo steady shifts in the market. Â Below is illustrated the 2009 (actual) and the 2019 (forecasted) revenues for the range of options that will be on the market.
Market for Obesity Management, 2009 & 2019
Source: Â MedMarket Diligence, LLC; Report #S835 (pending), “Products, Technologies and Markets Worldwide for the Clinical Management of Obesity, 2011-2019.”